- Home
- CPRI vs GPCR Comparison
CPRI vs GPCR Comparison
Compare CPRI & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPRI | GPCR |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CPRI | GPCR |
|---|---|---|
| Price | $18.27 | $37.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $26.62 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 3.2M | 618.0K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,474,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $16.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.49 | $15.80 |
| 52 Week High | $28.27 | $94.90 |
Technical Indicators
Market Signals| Indicator | CPRI | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 35.82 |
| Support Level | $16.82 | $35.78 |
| Resistance Level | $22.24 | $40.29 |
| Average True Range (ATR) | 0.89 | 1.93 |
| MACD | 0.11 | 0.50 |
| Stochastic Oscillator | 41.86 | 24.21 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.